AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reid, I. R.
Right arrow Articles by Ibbertson, H. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reid, I. R.
Right arrow Articles by Ibbertson, H. K.
Agricola
Right arrow Articles by Reid, I. R.
Right arrow Articles by Ibbertson, H. K.

American Journal of Clinical Nutrition, Vol 44, 287-290, Copyright © 1986 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Calcium supplements in the prevention of steroid-induced osteoporosis

IR Reid and HK Ibbertson

The long-term use of glucocorticoid drugs frequently results in the development of osteoporosis. To assess the value of calcium supplementation in preventing this loss of bone, the metabolic effects of administering 1 g of elemental calcium/day have been studied in 13 steroid-treated patients. After 2 mo, the fasting urine hydroxyproline- creatinine ratio decreased from 27.1 +/- 2.5 (SEM) to 21.8 +/- 2.4 (p less than 0.001) and there was an increase in fasting urine-calcium excretion (p less than 0.05). Serum alkaline phosphatase and osteocalcin showed no change. We concluded that calcium supplementation suppresses bone resorption without detectable suppression of indices of bone formation and is, therefore, likely to result in increased bone mass. The safety and low cost of calcium make it a very suitable prophylactic agent in glucocorticoid-treated patients.


This article has been cited by other articles:


Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
S. K. Shah and G. T. Gecys
Prednisone-Induced Osteoporosis: An Overlooked and Undertreated Adverse Effect
J Am Osteopath Assoc, November 1, 2006; 106(11): 653 - 657.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
I. R. Reid
Glucocorticoid Osteoporosis: Reid IR Glucocorticoid osteoporosis J Intensive Care Med 1999, 14231-242
J Intensive Care Med, September 1, 1999; 14(5): 231 - 242.
[PDF]

Home page
 Ann Rheum DisHome page
P. Geusens, J. Dequeker, J. Vanhoof, R. Stalmans, S. Boonen, J. Joly, J. Nijs, and J. Raus
Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study
Ann Rheum Dis, December 1, 1998; 57(12): 724 - 727.
[Abstract] [Full Text]

Home page
 Br. J. Ophthalmol.Home page
P HODGKINS, R G HULL, A R EVANS, and M N JEFFREY
Osteoporosis: a survey of consultant ophthalmologists
Br. J. Ophthalmol., April 1, 1997; 81(4): 260 - 260.
[Full Text] [PDF]

Home page
 NEJMHome page
P. Sambrook, J. Birmingham, P. Kelly, S. Kempler, T. Nguyen, N. Pocock, and J. Eisman
Prevention of Corticosteroid Osteoporosis -- A Comparison of Calcium, Calcitriol, and Calcitonin
N. Engl. J. Med., June 17, 1993; 328(24): 1747 - 1752.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by The American Society for Nutrition